Vice President Strategy, Planning & Operations, GlaxoSmithKlineAge:
To say that Eric Dube is committed to fighting cancer would be an understatement. The pharmaceutical executive not only led GlaxoSmithKline's $500 million U.S. oncology unit from 2008 until early 2011, but is also a survivor of the disease. Dube, who was diagnosed with testicular cancer in his early thirties, joined GSK in 2000 as a scientist. After proving his mettle in various marketing roles, he was promoted in 2008 to run the oncology unit, which launched three new cancer drugs during his tenure. Dube is currently working on revamping the operating model for GSK's U.S. pharmaceuticals division, which did $12 billion in sales last year.
NEXT: Clara Shih
EDITORIAL PACKAGE REPORTED BY KATIE BENNER, SCOTT CENDROWSKI, BETSY FELDMAN, MINA KIMES, ALEX KONRAD, BETH KOWITT, COLLEEN LEAHEY, MICHAL LEV-RAM, TARA MOORE, TORY NEWMYER, DANIEL ROBERTS, CHRISTOPHER TKACZYK, ANNE VANDERMEY @FortuneMagazine
- Last updated November 30 2011: 10:19 AM ET